Myeloid Derived Suppressor Cells (MDSCs) are increased and exert immunosuppressive activity together with Polymorphonuclear Leukocytes (PMNs) in chronic myeloid leukemia patients

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Giallongo, Cesarina ^a   Parrinello, Nunziatina ^a   Tibullo, Daniele ^a   La Cava, Piera ^a   Romano, Alessandra ^a   Chiarenza, Annalisa ^a   Barbagallo, Ignazio ^a   Palumbo, Giuseppe A ^a   Stagno, Fabio ^a   Vigneri, Paolo ^a   Di Raimondo, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ESSENTIAL AMINO ACID; IMATINIB; MESSENGER RNA; ARGINASE; ARGINASE I, HUMAN; CD11B ANTIGEN; CD14 ANTIGEN; CD33 ANTIGEN;

ADULT; AGED; ARTICLE; CELL EXPANSION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MIDDLE AGED; NEUTROPHIL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR MICROENVIRONMENT; YOUNG ADULT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; WESTERN BLOTTING;

ADULT; AGED; ANTIGENS, CD11B; ANTIGENS, CD14; ARGINASE; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEUTROPHILS; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84904182364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101848     Document Type: Article

References (51)

1. Davies J (2011) First-line therapy for CML: nilotinib comes of age. Lancet Oncol 12: 826-827.
2. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, et al. (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23: 1054-1061.
3. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
4. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92: 3362-3367. (Pubitemid 28492345)
5. Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K (2011) Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets 12: 420-428.
6. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, et al. (2010) Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363: 2511-2521.
7. Muller L, Pawelec G (2002) Chronic phase CML patients possess T cells capable of recognising autologous tumour cells. Leuk Lymphoma 43: 943-951. (Pubitemid 34460875)
8. Bertazzoli C, Marchesi E, Passoni L, Barni R, Ravagnani F, et al. (2000) Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients. Clin Cancer Res 6: 1931-1935. (Pubitemid 30305092)
9. Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, et al. (2000) Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol 111: 817-825. (Pubitemid 32098920)
10. Pawelec G, Rehbein A, Schlotz E, da Silva P (1996) Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. Cancer Immunol Immunother 42: 193-199. (Pubitemid 26153248)
11. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765. (Pubitemid 32368050)
12. Filipazzi P, Huber V, Rivoltini L (2011) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61: 255-263.
13. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
14. Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65. (Pubitemid 43139709)
15. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
16. Poschke I, Kiessling R (2012) On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 144: 250-268.
17. Chikamatsu K, Sakakura K, Toyoda M, Takahashi K, Yamamoto T, et al. (2012) Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci 103: 976-983.
18. Thakur A, Schalk D, Sarkar SH, Al-Khadimi Z, Sarkar FH, et al. (2011) A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol Immunother 61: 497-509.
19. Van Rompaey N, Le Moine A (2011) Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation. Methods Mol Biol 677: 169-180.
20. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P (2003) L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24: 302-306.
21. Huang B, Pan PY, Li Q, Sato AI, Levy DE, et al. (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131. (Pubitemid 43165981)
22. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22: 275-281.
23. Munder M, Mollinedo F, Calafat J, Canchado J, Gil-Lamaignere C, et al. (2005) Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood 105: 2549-2556. (Pubitemid 40387058)
24. Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, et al. (2012) Nuclear translocation of heme oxygenase-1 confers resistance to Imatinib in chronic myeloid leukemia cells. Curr Pharm Des.
25. Zitta K, Meybohm P, Bein B, Heinrich C, Renner J, et al. (2012) Serum from patients undergoing remote ischemic preconditioning protects cultured human intestinal cells from hypoxia-induced damage: involvement of matrixmetallo-proteinase-2 and -9. Mol Med 18: 29-37.
26. Lechner MG, Megiel C, Russell SM, Bingham B, Arger N, et al. (2011) Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 9: 90.
27. Hock BD, Taylor KG, Cross NB, Kettle AJ, Hampton MB, et al. (2012) Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability. Immunology 137: 249-258.
28. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, et al. (2012) Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 381: 14-22.
29. Bronte V, Zanovello P (2005) Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654. (Pubitemid 41113195)
30. Rotondo R, Bertolotto M, Barisione G, Astigiano S, Mandruzzato S, et al. (2011) Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol 89: 721-727.
31. Bachy E, Bernaud J, Roy P, Rigal D, Nicolini FE (2011) Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate. Br J Haematol 153: 139-143.
32. Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, et al. (2013) Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia. PLoS One 8: e55818.
33. Chen X, Liu S, Wang L, Zhang W, Ji Y, et al. (2008) Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther 7: 622-627.
34. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, et al. (2010) Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70: 99-108.
35. Rojas JM, Wang L, Owen S, Knight K, Watmough SJ, et al. (2010) Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. Exp Hematol 38: 1209-1218.
36. Hus I, Tabarkiewicz J, Lewandowska M, Wasiak M, Wdowiak P, et al. (2011) Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Folia Histochem Cytobiol 49: 153-160.
37. Mellqvist UH, Hansson M, Brune M, Dahlgren C, Hermodsson S, et al. (2000) Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 96: 1961-1968. (Pubitemid 30661084)
38. Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, et al. (2003) Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 101: 3560-3567. (Pubitemid 36857942)
39. Munder M, Schneider H, Luckner C, Giese T, Langhans CD, et al. (2006) Suppression of T-cell functions by human granulocyte arginase. Blood 108: 1627-1634. (Pubitemid 44316131)
40. Rotondo R, Barisione G, Mastracci L, Grossi F, Orengo AM, et al. (2009) IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer. Int J Cancer 125: 887-893.
41. Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, et al. (2011) Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One 6: e18534.
42. Finke J, Ko J, Rini B, Rayman P, Ireland J, et al. (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 11: 856-861.
43. Hiratsuka S, Watanabe A, Aburatani H, Maru Y (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8: 1369-1375. (Pubitemid 44835111)
44. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G (2011) S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 9: 133-148.
45. Condamine T, Gabrilovich DI (2011) Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 32: 19-25.
46. Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S (2012) Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother 35: 107-115.
47. Dumitru CA, Moses K, Trellakis S, Lang S, Brandau S (2012) Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 61: 1155-1167.
48. Brandau S, Moses K, Lang S (2013) The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol 23: 171-182.
49. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, et al. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
50. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, et al. (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122: 515-522.
51. Ohyashiki K, Katagiri S, Tauchi T, Ohyashiki JH, Maeda Y, et al. (2012) Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol 157: 254-256.